CA2508269A1 - Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination - Google Patents

Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination Download PDF

Info

Publication number
CA2508269A1
CA2508269A1 CA002508269A CA2508269A CA2508269A1 CA 2508269 A1 CA2508269 A1 CA 2508269A1 CA 002508269 A CA002508269 A CA 002508269A CA 2508269 A CA2508269 A CA 2508269A CA 2508269 A1 CA2508269 A1 CA 2508269A1
Authority
CA
Canada
Prior art keywords
study
patients
diuretic
trial
ecg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508269A
Other languages
English (en)
French (fr)
Inventor
Jefferson J. Gregory
Victoria Christian
Robert M. Califf
Raymond J. Lipicky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Publication of CA2508269A1 publication Critical patent/CA2508269A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002508269A 2002-12-16 2003-12-16 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination Abandoned CA2508269A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43384502P 2002-12-16 2002-12-16
US60/433,845 2002-12-16
PCT/US2003/041056 WO2004056360A1 (en) 2002-12-16 2003-12-16 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination

Publications (1)

Publication Number Publication Date
CA2508269A1 true CA2508269A1 (en) 2004-07-08

Family

ID=32681973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508269A Abandoned CA2508269A1 (en) 2002-12-16 2003-12-16 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination

Country Status (10)

Country Link
EP (1) EP1589965A1 (es)
JP (1) JP2006511567A (es)
KR (1) KR20050102080A (es)
CN (1) CN1731996A (es)
AU (1) AU2003303208A1 (es)
BR (1) BR0317326A (es)
CA (1) CA2508269A1 (es)
IL (1) IL169148A0 (es)
MX (1) MXPA05006399A (es)
WO (1) WO2004056360A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282519B2 (en) 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
EP1734931A2 (en) 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
US7396829B2 (en) 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
US9769354B2 (en) 2005-03-24 2017-09-19 Kofax, Inc. Systems and methods of processing scanned data
US9767354B2 (en) 2009-02-10 2017-09-19 Kofax, Inc. Global geographic information retrieval, validation, and normalization
US9576272B2 (en) 2009-02-10 2017-02-21 Kofax, Inc. Systems, methods and computer program products for determining document validity
US9165188B2 (en) 2012-01-12 2015-10-20 Kofax, Inc. Systems and methods for mobile image capture and processing
US10146795B2 (en) 2012-01-12 2018-12-04 Kofax, Inc. Systems and methods for mobile image capture and processing
US9355312B2 (en) 2013-03-13 2016-05-31 Kofax, Inc. Systems and methods for classifying objects in digital images captured using mobile devices
JP2016517587A (ja) 2013-03-13 2016-06-16 コファックス， インコーポレイテッド モバイル装置を用いて取込まれたデジタル画像におけるオブジェクトの分類
US9208536B2 (en) 2013-09-27 2015-12-08 Kofax, Inc. Systems and methods for three dimensional geometric reconstruction of captured image data
US20140316841A1 (en) 2013-04-23 2014-10-23 Kofax, Inc. Location-based workflows and services
DE202014011407U1 (de) 2013-05-03 2020-04-20 Kofax, Inc. Systeme zum Erkennen und Klassifizieren von Objekten in durch Mobilgeräte aufgenommenen Videos
JP2016538783A (ja) 2013-11-15 2016-12-08 コファックス， インコーポレイテッド モバイル映像データを用いて長尺文書の合成画像を生成するためのシステムおよび方法
US9760788B2 (en) 2014-10-30 2017-09-12 Kofax, Inc. Mobile document detection and orientation based on reference object characteristics
US10242285B2 (en) 2015-07-20 2019-03-26 Kofax, Inc. Iterative recognition-guided thresholding and data extraction
US9779296B1 (en) 2016-04-01 2017-10-03 Kofax, Inc. Content-based detection and three dimensional geometric reconstruction of objects in image and video data
US11062176B2 (en) 2017-11-30 2021-07-13 Kofax, Inc. Object detection and image cropping using a multi-detector approach
CN109524075A (zh) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 基于数据处理的药品费用超标风险控制方法及装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055904A (en) * 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN1731996A (zh) 2006-02-08
JP2006511567A (ja) 2006-04-06
BR0317326A (pt) 2005-11-16
WO2004056360A1 (en) 2004-07-08
AU2003303208A1 (en) 2004-07-14
KR20050102080A (ko) 2005-10-25
IL169148A0 (en) 2007-07-04
MXPA05006399A (es) 2006-01-27
EP1589965A1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
CA2508269A1 (en) Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination
Davis et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
Kannankeril et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial
Grimm Jr et al. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
Propranolol Aneurysm Trial Investigators Propranolol for small abdominal aortic aneurysms: results of a randomized trial
Wright et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril
Bittar Maintaining long‐term control of blood pressure: the role of improved compliance
Douglas et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Danchin et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials
Powell et al. Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial
Cohn et al. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice
Deedwania Hypertension and diabetes: new therapeutic options
Presta et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: analysis of a large real practice database in Italy
Neutel et al. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass
Smith et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study
Toto Angiotensin II subtype 1 receptor blockers and renal function
Bulik Abuse of drugs associated with eating disorders
Prisant et al. Hypertension in the elderly: can we improve results of therapy?
O’Brien et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber
TW202140058A (zh) 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
Basile et al. Identifying and managing factors that interfere with or worsen blood pressure control
Moak et al. Median arcuate ligament syndrome with orthostatic intolerance: intermediate-term outcomes following surgical intervention
Topouzis et al. Brinzolamide/brimonidine fixed-dose combination Bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
MXPA06004369A (es) Uso de compuestos organicos.
Blank et al. Managing multiple cardiovascular risk factors

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20070905